Proton Biopharma

Proton Biopharma is a UK-based biotechnology company focused on the development of novel small molecule inhibitors targeting cancer metabolism. The company's lead program, PB-101, is a first-in-class inhibitor of the proton-coupled amino acid transporter 1 (PAT1), a protein that is frequently overexpressed in solid tumors and is essential for the uptake of nutrients required for rapid cell proliferation. By targeting PAT1, Proton Biopharma aims to disrupt the metabolic pathways that sustain tumor growth and survival, particularly in cancers that have become resistant to standard therapies. Led by a team of experienced biotech executives, the company is advancing its pipeline through pre-clinical development with the goal of entering clinical trials for various oncology indications.